Emerging Pharmaceutical Sales & Marketing Company CaraMedica Closes Series A Funding Round

Research Triangle Park, NC, December 21, 2005 --(PR.com)-- CaraMedica Pharmaceuticals, Inc., an emerging pharmaceutical sales, marketing and development company focused on the cosmetic surgery market, announced today that it has successfully completed a Series A round of funding.

 “We secured our initial investment on more favorable terms from the angel investment community and were oversubscribed,” said Damon Race, CEO of CaraMedica. “This funding allows us to market our products to cosmetic surgeons and dermatologists nationwide.”

According to the American Society for Aesthetic Plastic Surgery, approximately 11.9 million cosmetic procedures were performed in America in 2004, a 44% increase from the previous year.  CaraMedica is well positioned to capitalize on this growth with a portfolio of branded after care products that enable patients to shorten recovery time, accelerate results and extend the benefits of the surgery.

"We are proud to be associated with this exciting early stage company. The financing round is a testament to the investment community's recognition of the entrepreneurial management team's ability to execute on the company's innovative concept," commented Merrill Mason of Hutchison & Mason, CaraMedica's law firm.

###

About CaraMedica Pharmaceuticals, Inc.
CaraMedica Pharmaceuticals is an emerging marketing, sales and development company based in Research Triangle Park, North Carolina.  CaraMedica offers cosmetic surgeons and dermatologists an exclusive portfolio of patented and proprietary prescription, cosmeceutical and nutraceutical products.